CME Presentations

EGFR TKI-Resistant NSCLC and HER2-Positive NSCLC



  • Lyudmila Bazhenova, MD

    Lyudmila Bazhenova, MD

    Lyudmila Bazhenova, MD

    Program Director

    Lyudmila Bazhenova, MD, is a Program Director for Hematology Oncology fellowship training program. Her clinical practice is devoted to patients with all types of lung cancer, and she has expertise in patients with driver mutations, female patients, and nonsmokers. Currently, Dr. Bazhenova leads Lung Cancer group at UCSD and has over 15 years of experience in managing patients with lung cancer. She believes in a multidisciplinary approach to lung cancer and works closely with surgical and radiation oncologists to provide the best patient experience. Dr. Bazhenova is also an active participant in clinical research, including designing and implementing clinical investigations at Moores Cancer Center. Furthermore, she is a member of respiratory committee of Alliance cooperative group.
  • Pasi Jänne, MD, PhD

    Pasi Jänne, MD, PhD

    Pasi Jänne, MD, PhD

    Professor of Medicine

    Pasi Jänne, MD, PhD, is the Director of the Lower Center for Thoracic Oncology and the David M. Livingston, MD Chair at Dana-Farber Cancer Institute, and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute and Director of the Chen-Huang Center for EGFR Mutant Cancers. Dr. Jänne’s research combines laboratory-based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. Furthermore, he has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations, and findings from his work has led to the development of several clinical trials and new therapies for lung cancer patients.

CME Information

Global Logo PQH Logo
Expert Insight into Emerging Treatments for EGFR TKI-Resistant NSCLC and HER2-Positive NSCLC
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.


This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo Inc.


This activity was released on February 15, 2023 and is valid until February 14, 2024. Requests for credit must be made no later than February 15, 2024


Medical oncologists, thoracic oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other HCPs managing patients with NSCLC


Despite substantial advances in the management of non-small cell lung cancer (NSCLC) during the past decade, advanced NSCLC continues to have persistently low 5-year survival rates and imposes a significant burden on patients. Improved molecular-testing practices and integration of new data on targeted treatments could inform treatment decision-making and help clinicians optimize patient care.

Join a panel of experts from the thoracic oncology team to discuss the clinical relevance of HER2 and HER3 status in the treatment of NSCLC. Panelists will explore the identification of actionable mutations in patients with newly diagnosed NSCLC and review how to select appropriate assays for molecular testing. Experts will also look at the landscape of current and emerging targeted therapies and discuss how to account for individual clinical characteristics and mitigate potential adverse effects


After completing this activity, the participant should be better able to:
  • Illustrate appropriate testing to identify clinically relevant mutations
  • Appraise current and emerging targeted therapies for NSCLC, including mechanisms of action, key trial data, and strategies to manage potential side effects


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated. The faculty have the following relevant financial relationships with ineligible companies:

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Lyudmila Bazhenova, MD
University of California, San Diego
Professor of Medicine
Lung Cancer Unit Leader
Director, Hematology and Oncology Training Program
University of California, San Diego
Consulting Fee: Janssen, Turning Point, Daichi, Merck, Neuvogen, Genentech, ORIC, Sanofi, Bayer, Regeneron, Novocure, Zai Labs, levation oncology, Intervenn, Abbvie
Pasi Janne, MD
Director, Lowe Center for Thoracic Oncology
Director, Belfer Center for Applied Cancer Science
Director, Chen-Huang Center for EGFR Mutant Lung Cancers
Senior Physician
Professor of Medicine, Harvard Medical School
Consulting Fee: AstraZeneca; Boehringer Ingelheim; Pfizer; Roche/Genentech; Chugai Pharmaceuticals; Eli Lilly pharmaceuticals; SF J Pharmaceuticals; Voronoi; Daiichi Sankyo; Biocartis; Novartis; Sanofi; Takeda Oncology; Mirati Therapeutics; Transcenta; Silicon Therapeutics; Syndax; Nuvalent; Bayer; Eisai; Allorion Therapeutics; Accutar Biotech; Abbvie; Monte Rosa; Scorpion Therapeutics; Merus; Frontier Medicines; Hongyun Biotechnology; Duality
Contracted Research: AstraZenenca; Daiichi Sankyo; PUMA; Eli Lilly pharmaceuticals; Boehringer Ingelheim; Revolution Medicines; Takeda Oncology
Royalty: Labcorp

The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at